NLRP3 and muscle atrophy: Moreover, LPS/ATP treatment also resulted in increased expression of atrophy markers, Atrogin-1 and MuRF1, indicating that trimetazidine may attenuate dexamethasone-induced muscle atrophy via inhibiting NLRP3-mediated pyroptosis.